Should we pay for drugs or cures? How tracking drug effectiveness could improve US healthcare spending

by Dan Tarjan  figures by Krissy Lyon The EpiPen, the antiparasitic drug Daraprim, the blood pressure medication Nitropress. These life saving drugs have recently been in the news because their prices spiked by over 100% year-to-year without any apparent reason except increasing profits. And they’re not alone. Across the US healthcare industry, specialty drug prices are rising. These brand name products marked a 16.2% increase … Continue reading Should we pay for drugs or cures? How tracking drug effectiveness could improve US healthcare spending